MindWalk Holdings Corp. HYFT 深 沪
已收盘 07-10 16:00:00 美东时间
1.43
-0.030
-2.05%
华盛通- 最 高1.47
- 今 开1.47
- 成交量 14.03万股
- 最 低 1.39
- 昨 收 1.46
- 总市值 6679.80万
- 52周最高 3.2459
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 0.99
- 委 比 36.62%
- 总股本 4671.19万
- 历史最高 33.34
- 量 比 0.51
- 振 幅 5.48%
- 历史最低 0.27
- 每 手 1
- 风险率 0.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MindWalk Joins Russell 3000 Index, Effective June 26
MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was ...
07-06 20:40
MindWalk Files European Patent Application Directed To High-Dimensional Data Structures For Biological Subsequences And Property Inference
The patent covers the multi-dimensional biological representation layer organized around MindWalk’s HYFT® pattern anchors — the model-agnostic context layer designed to support ReefIQ™, LensAI™, and customer-selected AI workflows as they retrieve, compare, and reason over connected, traceable biolog...
07-01 20:08
MindWalk Holdings Reports Preclinical Dengue Data Supporting Computational Prediction Its HYFT Platform Generated Before Any Animal Was Immunized
HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the prediction at the binding level: immunization with immunogens designed on
06-02 19:23
埃博拉与汉坦病毒暴露传统疫苗短板，MindWalk推出AI大流行应对平台
针对当前埃博拉和汉坦病毒疫情暴露出的传统应变特异性疫苗的局限性，生物科技公司MindWalk Holdings Corp.(HYFT)5月27日宣布正式启动...
05-27 22:48
MindWalk Highlights 20-Plus Partner Drug Programs Tied to Its Discovery Platform
An announcement from MindWalk Holdings ( ($HYFT) ) is now available. MindWalk H...
05-18 22:46
MindWalk reports 10 partner-owned antibody programs in active Phase 1-3 trials
MindWalk reports 10 partner-owned antibody programs in active Phase 1-3 trials MindWalk Holdings released a report in May 2026 attributing more than 20 drug candidates that reached clinical trials to antibody discovery work conducted at its facilities. Ten partner-owned programs were described as ac
05-18 21:55
MindWalk publishes Discovery-to-Clinic presentation factsheet
MindWalk publishes Discovery-to-Clinic presentation factsheet MindWalk Holdings published a Discovery-to-Clinic presentation detailing more than 20 partner-owned drug candidates originating from its antibody discovery work, including 10 programs in active Phase 1-3 clinical trials. Highlighted clini
05-18 20:36
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
Jones Trading Initiates Coverage On MindWalk Holdings with Buy Rating, Announces Price Target of $5
Jones Trading analyst Debanjana Chatterjee initiates coverage on MindWalk Holdings (NASDAQ:HYFT) with a Buy rating and announces Price Target of $5.
04-17 02:48
MindWalk Holdings insiders deploy USD 73,238 to raise holdings to 3.98%
MindWalk Holdings insiders deploy USD 73,238 to raise holdings to 3.98% Dirk Van Hyfte bought 30,000 MindWalk common shares in open-market trades at an average price of USD 1.22 per share. Ingrid Brands bought 30,000 common shares via Charmquark TWEE at an average price of USD 1.22 per share. Combin
03-23 20:53
